Chiesi Farmaceutici SpA の製品パイプライン分析2016

◆英語タイトル:Chiesi Farmaceutici SpA - Product Pipeline Review - 2016
◆商品コード:DATA70209174
◆発行会社(調査会社):Global Markets Direct
◆発行日:2016年10月12日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥162,000見積依頼/購入/質問フォーム
Site LicenseUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Chiesi Farmaceutici SpA – Product Pipeline Review – 2016
Summary

Global Markets Direct’s, ‘Chiesi Farmaceutici SpA – Product Pipeline Review – 2016’, provides an overview of the Chiesi Farmaceutici SpA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chiesi Farmaceutici SpA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Chiesi Farmaceutici SpA
- The report provides overview of Chiesi Farmaceutici SpA including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Chiesi Farmaceutici SpA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Chiesi Farmaceutici SpA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Chiesi Farmaceutici SpA’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chiesi Farmaceutici SpA
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chiesi Farmaceutici SpA’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Chiesi Farmaceutici SpA Snapshot 6
Chiesi Farmaceutici SpA Overview 6
Key Facts 6
Chiesi Farmaceutici SpA – Research and Development Overview 7
Key Therapeutic Areas 7
Chiesi Farmaceutici SpA – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
Pipeline Products – Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products – Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Chiesi Farmaceutici SpA – Pipeline Products Glance 17
Chiesi Farmaceutici SpA – Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Chiesi Farmaceutici SpA – Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Chiesi Farmaceutici SpA – Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Chiesi Farmaceutici SpA – Unknown Stage Pipeline Products 21
Unknown Products/Combination Treatment Modalities 21
Chiesi Farmaceutici SpA – Drug Profiles 22
(beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) – Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
budesonide – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CHF-5633 – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
CHF-6001 – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CHF-6297 – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CPD-15 – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Drugs for Bronchopulmonary Dysplasia – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
glycopyrrolate – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
melatonin – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
meropenem – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Recombinant Enzymes for Rare Diseases – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Recombinant Protein for Neonatal Respiratory Distress Syndrome – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Recombinant Protein to Target NGF for Undisclosed Indication – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule to Target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules for Neonatal Abstinence Syndrome – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
TRP-601 – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
velmanase alfa – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Chiesi Farmaceutici SpA – Pipeline Analysis 45
Chiesi Farmaceutici SpA – Pipeline Products by Target 45
Chiesi Farmaceutici SpA – Pipeline Products by Route of Administration 47
Chiesi Farmaceutici SpA – Pipeline Products by Molecule Type 48
Chiesi Farmaceutici SpA – Pipeline Products by Mechanism of Action 49
Chiesi Farmaceutici SpA – Dormant Projects 51
Chiesi Farmaceutici SpA – Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 53
beclomethasone dipropionate SR 53
carmoterol 53
indantadol 53
Porphozym 53
Chiesi Farmaceutici SpA – Company Statement 54
Chiesi Farmaceutici SpA – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 57
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables
Chiesi Farmaceutici SpA, Key Facts 6
Chiesi Farmaceutici SpA - Pipeline by Indication, 2016 9
Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2016 10
Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2016 11
Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2016 12
Chiesi Farmaceutici SpA - Partnered Products in Pipeline, 2016 13
Chiesi Farmaceutici SpA - Partnered Products/ Combination Treatment Modalities, 2016 14
Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2016 15
Chiesi Farmaceutici SpA - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Chiesi Farmaceutici SpA - Phase III, 2016 17
Chiesi Farmaceutici SpA - Phase II, 2016 18
Chiesi Farmaceutici SpA - Phase I, 2016 19
Chiesi Farmaceutici SpA - Preclinical, 2016 20
Chiesi Farmaceutici SpA - Unknown, 2016 21
Chiesi Farmaceutici SpA - Pipeline by Target, 2016 46
Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2016 47
Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2016 48
Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action, 2016 50
Chiesi Farmaceutici SpA - Dormant Developmental Projects,2016 51
Chiesi Farmaceutici SpA - Discontinued Pipeline Products, 2016 52
Chiesi Farmaceutici SpA, Subsidiaries 57

List of Figures
Chiesi Farmaceutici SpA - Pipeline by Top 10 Indication, 2016 8
Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2016 10
Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2016 11
Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2016 12
Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2016 15
Chiesi Farmaceutici SpA - Pipeline by Top 10 Target, 2016 45
Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2016 47
Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2016 48
Chiesi Farmaceutici SpA - Pipeline Products by Top 10 Mechanism of Action, 2016 49

★調査レポート[Chiesi Farmaceutici SpA の製品パイプライン分析2016] (コード:DATA70209174)販売に関する免責事項を必ずご確認ください。
★調査レポート[Chiesi Farmaceutici SpA の製品パイプライン分析2016]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆